Last reviewed · How we verify
NCT03766425
Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.
EARLY_PHASE1 trial testing Aflibercept in Eye Diseases in 64 participants. Completed in 31 July 2019.
31 July 2019
Quick facts
| Lead sponsor | Medical University of Lublin |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 64 |
| Start date | 14 June 2017 |
| Primary completion | 31 July 2019 |
| Estimated completion | 31 July 2019 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Aflibercept (AFLIBERCEPT) — full drug profile →
- Mitomycin (MITOMYCIN) — full drug profile →
Conditions studied
- Eye Diseases — all drugs for Eye Diseases →
- Optic Nerve Damage — all drugs for Optic Nerve Damage →
- Glaucoma Surgery — all drugs for Glaucoma Surgery →
Sponsor
Medical University of Lublin
Who can join
40 and older, any sex, with Eye Diseases or Optic Nerve Damage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Comparison of efficacy and safety of Mitomycin and Aflibercept used to support primary trabeculectomy - a prospective, randomized trial in patients with open-angle glaucoma undergoing surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03766425
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Aflibercept
Trials testing the same drug.
- NCT07496567 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) · Phase 2, PHASE3 · not yet recruiting
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT07482176 — Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Deg · Phase 3 · recruiting
- NCT06856577 — Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Deg · Phase 3 · recruiting
- NCT06839339 — Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD · Phase 2 · not yet recruiting
Other recruiting trials for Eye Diseases
Currently open trials in the same condition.
- NCT07322302 — RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs) · NA · recruiting
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
- NCT06812845 — Patterns of Eye Diseases Among Patients Attending The Eye Investigation Unit of Sohag University Hospital · recruiting
- NCT06601101 — Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus · Phase 3 · recruiting
Other Medical University of Lublin trials
Trials by the same sponsor.
- NCT07085286 — Perfusion Related Evaluation of Systemic and Renal Vulnerability to Events in CABG · not yet recruiting
- NCT06897436 — Characterization of Immune Cells and Their Secreted Cytokines in Endometriosis Patients · not yet recruiting
- NCT06516835 — Diluted and Undiluted Enteral Nutrition · NA · not yet recruiting
- NCT07182318 — Validation of the FIGO Nutrition Checklist in Pregnant Women · completed
- NCT06282666 — Lumbar ESPB in Hip Replacement Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03766425 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Lublin
- Last refreshed: 27 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03766425.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing